

Freedom of Information request 534-23

Request & Response

1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- | | |
|---|-------------------|
| • CAPOX (Capecitabine with Oxaliplatin) | 0 |
| • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) | 0 |
| • Lonsurf (Trifluridine - tipiracil) | 0 |
| • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) | 0 |
| • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) | 0 |
| • Any other systemic anti-cancer therapy | 0 |
| • Palliative care only | Not Held * |

2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- | | |
|---|-------------------|
| • Nivolumab monotherapy or combination with Ipilimumab | <5 |
| • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) | 0 |
| • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) | 0 |
| • Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) | <5 |
| • Any other systemic anti-cancer therapy | <5 |
| • Palliative care only | Not Held * |

3. How many patients were treated in the past 3 months for advanced/metastatic resected oesophageal cancer ONLY with:

- | | |
|---|-------------------|
| • Nivolumab monotherapy or combination with Ipilimumab | <5 |
| • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) | 0 |
| • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) | 0 |
| • Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) | <5 |
| • Any other systemic anti-cancer therapy | <5 |
| • Palliative care only | Not Held * |

4. In the past 3 months, how many patients have been initiated* on the following agents for treatment for gastric, gastro-oesophageal junction or Oesophageal cancer:

- Nivolumab monotherapy or in combination with Ipilimumab 0
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) 0

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

5. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.

NHS Borders does not currently participate in any clinical trials for Gastric Cancer.

6. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.

NHS Borders does not currently participate in any clinical trials for Oesophageal Cancer.

Please note, Not Held * = This information is not held electronically. The data may be held in a patient's record, but to extract this data would require a manual trawl of all patient records and the cost of carrying out this work would exceed the limit set in the Fees Regulations of the Freedom of Information (Scotland) Act 2002 and under Section 12 we are not required to provide.

As the number of events in some areas are very small and in accordance with the Code of Practice for Official Statistics any number that is less than five, actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the [ISD Statistical Disclosure Control Protocol](#).

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **534-23** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.